Puma Biotechnology Inc. (NYSE:PBYI) has been assigned a consensus recommendation of “Buy” from the ten research firms that are currently covering the firm. One analyst has rated the stock with a sell recommendation, three have given a hold recommendation and six have issued a buy recommendation on the company. The average 12 month price target among analysts that have covered the stock in the last year is $71.79.
Several research firms have recently issued reports on PBYI. Zacks Investment Research lowered Puma Biotechnology from a “hold” rating to a “sell” rating in a report on Tuesday, June 7th. Citigroup Inc. set a $88.00 target price on Puma Biotechnology and gave the company a “buy” rating in a report on Tuesday, September 20th. JPMorgan Chase & Co. set a $89.00 target price on Puma Biotechnology and gave the company a “buy” rating in a report on Tuesday, September 20th. Credit Suisse Group AG upped their target price on Puma Biotechnology from $54.00 to $111.00 and gave the company an “outperform” rating in a report on Thursday, September 22nd. Finally, Stifel Nicolaus reissued a “hold” rating on shares of Puma Biotechnology in a report on Sunday, July 24th.
Large investors have recently bought and sold shares of the company. Franklin Street Advisors Inc. NC increased its stake in shares of Puma Biotechnology by 3.0% in the second quarter. Franklin Street Advisors Inc. NC now owns 34,025 shares of the biopharmaceutical company’s stock worth $1,014,000 after buying an additional 980 shares during the period. Iguana Healthcare Management LLC increased its stake in shares of Puma Biotechnology by 16.3% in the first quarter. Iguana Healthcare Management LLC now owns 29,070 shares of the biopharmaceutical company’s stock worth $854,000 after buying an additional 4,070 shares during the period. Orbis Allan Gray Ltd acquired a new stake in shares of Puma Biotechnology during the first quarter worth about $1,288,000. Bogle Investment Management L P DE acquired a new stake in shares of Puma Biotechnology during the first quarter worth about $4,730,000. Finally, Geode Capital Management LLC increased its stake in shares of Puma Biotechnology by 2.2% in the first quarter. Geode Capital Management LLC now owns 129,935 shares of the biopharmaceutical company’s stock worth $3,816,000 after buying an additional 2,773 shares during the period. Hedge funds and other institutional investors own 97.53% of the company’s stock.
Puma Biotechnology (NYSE:PBYI) opened at 67.05 on Thursday. Puma Biotechnology has a 52 week low of $19.74 and a 52 week high of $94.93. The company’s market cap is $2.18 billion. The stock has a 50 day moving average price of $59.44 and a 200 day moving average price of $40.52.
Puma Biotechnology (NYSE:PBYI) last released its earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($1.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.18) by $1.01. On average, equities analysts forecast that Puma Biotechnology will post ($8.12) earnings per share for the current year.
About Puma Biotechnology
Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the global development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), which the Company is developing for the treatment of patients with human epidermal growth factor receptor type 2 (HER2), positive breast cancer, and patients with non-small cell lung cancer, breast cancer and other solid tumors that have a HER2 mutation; PB272 (neratinib (intravenous)), which the Company is developing for the treatment of patients with advanced cancer, and PB357, which is an orally administered agent.
Receive News & Ratings for Puma Biotechnology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.